Back to results
US 7,608,591 B2Granted
Targeted delivery to legumain-expressing cells
AssigneeThe Scripps Research Institute
InventorsCheng Liu, Thomas S. Edgington
Life of this patent
Estimating the term…
Abstract
The present invention relates to new agents and methods useful for preventing, treating and diagnosing diseases such as cancer. For example, the invention relates to prodrug agents useful for targeting and delivering cytotoxic drugs to cancerous cells.
Claims17
A prodrug compound, comprising cytosine arabinoside or doxorubicin linked to a legumain peptide substrate having a peptide consisting of amino acid sequence Ala-Ala-Asn-Leu (SEQ ID NO:5) and wherein legumain cleaves the peptide at the link between the Asn and another amino acid to generate active cytosine arabinoside or doxorubicin from the prodrug.
Dependencies are inferred from the claim text.